172 related articles for article (PubMed ID: 32145345)
1. Targeting BCL-2 proteins in pediatric cancer: Dual inhibition of BCL-X
Kehr S; Haydn T; Bierbrauer A; Irmer B; Vogler M; Fulda S
Cancer Lett; 2020 Jul; 482():19-32. PubMed ID: 32145345
[TBL] [Abstract][Full Text] [Related]
2. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.
Ewald L; Dittmann J; Vogler M; Fulda S
Cell Death Dis; 2019 Dec; 10(12):917. PubMed ID: 31801941
[TBL] [Abstract][Full Text] [Related]
3. A direct comparison of selective BH3-mimetics reveals BCL-X
Bierbrauer A; Jacob M; Vogler M; Fulda S
Br J Cancer; 2020 May; 122(10):1544-1551. PubMed ID: 32203216
[TBL] [Abstract][Full Text] [Related]
4. BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-X
Greaves G; Milani M; Butterworth M; Carter RJ; Byrne DP; Eyers PA; Luo X; Cohen GM; Varadarajan S
Cell Death Differ; 2019 Jun; 26(6):1037-1047. PubMed ID: 30185825
[TBL] [Abstract][Full Text] [Related]
5. S63845, an MCL-1 Selective BH3 Mimetic: Another Arrow in Our Quiver.
Letai A
Cancer Cell; 2016 Dec; 30(6):834-835. PubMed ID: 27960083
[TBL] [Abstract][Full Text] [Related]
6. Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-x
Peng Z; Gillissen B; Richter A; Sinnberg T; Schlaak MS; Eberle J
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542429
[TBL] [Abstract][Full Text] [Related]
7. XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis.
Zhu ZC; Liu JW; Yang C; Zhao M; Xiong ZQ
Cell Death Dis; 2019 May; 10(6):395. PubMed ID: 31113936
[TBL] [Abstract][Full Text] [Related]
8. Mcl-1 targeting strategies unlock the proapoptotic potential of TRAIL in melanoma cells.
Sarif Z; Tolksdorf B; Fechner H; Eberle J
Mol Carcinog; 2020 Nov; 59(11):1256-1268. PubMed ID: 32885857
[TBL] [Abstract][Full Text] [Related]
9. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N
Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848
[TBL] [Abstract][Full Text] [Related]
10. Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.
Merino D; Whittle JR; Vaillant F; Serrano A; Gong JN; Giner G; Maragno AL; Chanrion M; Schneider E; Pal B; Li X; Dewson G; Gräsel J; Liu K; Lalaoui N; Segal D; Herold MJ; Huang DCS; Smyth GK; Geneste O; Lessene G; Visvader JE; Lindeman GJ
Sci Transl Med; 2017 Aug; 9(401):. PubMed ID: 28768804
[TBL] [Abstract][Full Text] [Related]
11. MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells.
Wang Q; Wan J; Zhang W; Hao S
Leuk Lymphoma; 2019 Sep; 60(9):2170-2180. PubMed ID: 30626241
[TBL] [Abstract][Full Text] [Related]
12. BCL-x
Faqar-Uz-Zaman SF; Heinicke U; Meister MT; Vogler M; Fulda S
Cancer Lett; 2018 Jan; 412():131-142. PubMed ID: 28947136
[TBL] [Abstract][Full Text] [Related]
13. Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 protein.
Preuss E; Hugle M; Reimann R; Schlecht M; Fulda S
J Biol Chem; 2013 Dec; 288(49):35287-96. PubMed ID: 24133218
[TBL] [Abstract][Full Text] [Related]
14. MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-X
Yasuda Y; Ozasa H; Kim YH; Yamazoe M; Ajimizu H; Yamamoto Funazo T; Nomizo T; Tsuji T; Yoshida H; Sakamori Y; Nakajima N; Menju T; Yoshizawa A; Date H; Hirai T
Cell Death Dis; 2020 Mar; 11(3):177. PubMed ID: 32152266
[TBL] [Abstract][Full Text] [Related]
15. Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance.
Alcon C; Manzano-Muñoz A; Prada E; Mora J; Soriano A; Guillén G; Gallego S; Roma J; Samitier J; Villanueva A; Montero J
Cell Death Dis; 2020 Aug; 11(8):634. PubMed ID: 32801295
[TBL] [Abstract][Full Text] [Related]
16. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Chen S; Dai Y; Harada H; Dent P; Grant S
Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
[TBL] [Abstract][Full Text] [Related]
17. Co-inhibition of BCL-XL and MCL-1 with selective BCL-2 family inhibitors enhances cytotoxicity of cervical cancer cell lines.
Abdul Rahman SF; Muniandy K; Soo YK; Tiew EYH; Tan KX; Bates TE; Mohana-Kumaran N
Biochem Biophys Rep; 2020 Jul; 22():100756. PubMed ID: 32346617
[TBL] [Abstract][Full Text] [Related]
18. Co-inhibition of BET proteins and PI3Kα triggers mitochondrial apoptosis in rhabdomyosarcoma cells.
Boedicker C; Hussong M; Grimm C; Dolgikh N; Meister MT; Enßle JC; Wanior M; Knapp S; Schweiger MR; Fulda S
Oncogene; 2020 May; 39(19):3837-3852. PubMed ID: 32161312
[TBL] [Abstract][Full Text] [Related]
19. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
[TBL] [Abstract][Full Text] [Related]
20. Hypertonicity counteracts MCL-1 and renders BCL-XL a synthetic lethal target in head and neck cancer.
Heimer S; Knoll G; Neubert P; Hammer KP; Wagner S; Bauer RJ; Jantsch J; Ehrenschwender M
FEBS J; 2021 Mar; 288(6):1822-1838. PubMed ID: 32710568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]